Symbol | Exchange | Currency |
---|
Investing.com – U.S. stocks were mixed after the close on Friday, as gains in the Consumer Goods, Utilities and Financials sectors led shares higher while losses in the Technology,...
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Sell | Sell | Sell | Buy |
Technical Indicators | Neutral | Strong Buy | Strong Sell | Sell | Neutral |
Summary | Neutral | Neutral | Strong Sell | Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
18.46 | 18.53 | 17.85 | +0.11 | +0.60% | 163.54K | NASDAQ | |||
352.08 | 353.44 | 350.86 | -1.66 | -0.47% | 447.14K | NYSE | |||
90.40 | 91.88 | 88.52 | +0.63 | +0.70% | 9.84M | NYSE | |||
7.63 | 7.72 | 7.63 | 0.00 | 0.00% | 2.66M | NASDAQ | |||
16.01 | 16.08 | 15.86 | -0.02 | -0.11% | 22.81M | NYSE | |||
244.58 | 246.48 | 239.28 | +3.43 | +1.42% | 2.86M | NASDAQ | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
50.55 | 51.35 | 48.45 | +2.71 | +5.67% | 3.97M | NYSE | |||
64.94 | 65.10 | 64.71 | +0.06 | +0.09% | 2.24M | NYSE | |||
1.44 | 1.53 | 1.30 | -0.060 | -4.00% | 233.12K | NASDAQ | |||
2.866 | 3.29 | 2.835 | -0.384 | -11.81% | 8.80M | NASDAQ | |||
1.87 | 2.05 | 1.86 | -0.19 | -9.26% | 1.23M | NASDAQ | |||
4.91 | 5.03 | 4.67 | -0.17 | -3.35% | 41.76M | NYSE | |||
18.34 | 20.81 | 16.16 | -4.74 | -20.52% | 104.61M | NASDAQ | |||
0.705 | 0.711 | 0.67 | +0.005 | +0.73% | 302.22K | NASDAQ |